|
Patent landscape, scope, and claims: |
United States Patent 8,471,025 (trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide) Crystalline Form Claim Scope and Patent Landscape Analysis
What is US Patent 8,471,025 claiming and what is its practical scope?
US 8,471,025 is directed to crystalline solid forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (and pharmaceutically acceptable salts), where the claimed invention is defined by specific XRPD peak and d-spacing parameters. The active claim set is largely “crystal-spec” coverage, not dosage-form or process coverage.
Core claim construction: XRPD-defined crystalline forms
From the provided claim text, the invention scope is anchored on:
- A specific polymorph family of the same molecular entity (trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide), including pharmaceutically acceptable salts.
- XRPD fingerprints expressed as:
- Characteristic peak positions (2θ, degrees) with a ±0.5° tolerance, and/or
- d-spacing values (nm) with a ±0.2 nm tolerance, and
- multi-peak patterns that collectively characterize a crystalline form.
Most decision-relevant independent claim language
- Claim 1: A crystalline form defined by an XRPD characteristic peak at ~13.0 and ~17.3 ±0.5° (2θ) for the free base or salt.
- Claim 11: A more complete fingerprint version listing many peaks (15+ peaks).
- Claims 12-16: Alternative d-spacing-based definitions with multiple d-spacings and tolerances.
- Claims 17-18 and 19-26: Additional enumerated XRPD patterns that pick out additional crystalline forms (or sub-varieties) using peak lists or d-spacing lists.
- Claim 27-34: More crystalline-form variants specified by d-spacing pair or set constraints.
Business meaning: infringement/avoidance pivots on whether a competitor’s solid state material matches the asserted XRPD peak locations or d-spacings within the stated tolerances under comparable measurement conditions.
How broad is the protection: peak-by-peak vs fingerprint-style claims?
The patent uses both “minimal-peaks” and “full-pattern” claim strategies. That mix matters for enforcement leverage.
1) Narrow gate claims (few peaks)
- Claim 1: requires two peaks at about 13.0 and 17.3 ±0.5°.
- Claim 19: requires peaks at about 8.5 and about 24.3 ±0.5°.
- Claim 21: requires peaks at about 17.8 and about 18.6 ±0.5°.
- Claim 2-10, 20, 22-26: dependent claims tighten to a specific salt (sodium) and/or add additional peaks.
Impact: “two-peak” gating can capture multiple physical outcomes if the material’s XRPD includes those peaks even if other peaks differ, depending on claim interpretation and the likelihood that those peaks are unique to a single polymorph under the same measurement regime.
2) Breadth via expanded enumerations
- Claim 11 and other “long list” claims require many peak positions within tolerances.
- Claims 12, 18, 22, 24, 30, 32, 34: require multiple d-spacing values across the pattern.
Impact: these claims typically require closer structural identity of the polymorph (or a closely related form), improving validity defensibility but raising the bar for proof in infringement.
Which crystalline forms are covered: sodium salt vs free base?
Salt scope is explicit and selectively mandatory. The claim set shows:
- Claim 1 includes free base or pharmaceutically acceptable salt.
- Claim 2 narrows to the sodium salt of the named compound with stereochemical descriptor (1R,2S,5R)-...carboxamide.
- Multiple dependent claims (3-10) build off Claim 2’s sodium salt limitation and then define specific XRPD peaks.
Enforcement leverage
- A competitor using non-sodium salts (e.g., other pharmaceutically acceptable salts) may still face Claim 1 if their polymorph matches the free-base/salt XRPD gate.
- A competitor using the sodium salt increases risk because dependent claims (2→3/4/5/6/7/8/9/10) articulate sodium-specific XRPD patterns.
What do the peak tolerances imply for infringement and design-around?
The claims use:
- ±0.5° 2θ tolerance on peak positions.
- ±0.2 nm tolerance on d-spacings.
Practical IP risk mechanics
- If a competitor’s material shows the same hallmark peaks/d-spacings within tolerances, XRPD match likely supports infringement of the relevant crystal-form claim.
- A competitor can attempt design-around by:
- generating a different polymorph with shifted peak positions beyond tolerance, or
- using a solid-state form with partial overlap but lacking one required hallmark peak.
Key strategic observation
Because several claims use two-hallmark peak pairs as gating (claims 1, 19, 21), design-around may require shifting at least one of those hallmark peaks outside ±0.5° under the relevant measurement protocol.
How many distinct crystalline-form “variants” are effectively claimed?
Based on the provided text alone, the patent appears to cover multiple crystalline-form variants, each separated by:
- distinct peak pairs (claims 1, 19, 21),
- distinct multi-peak lists (claims 10, 11, 17, 20, 22, 24, 26),
- distinct d-spacing sets (claims 12-16, 18, 27-34).
Counting method (from provided claims):
- Independent entry points: Claim 1, Claim 11, Claim 12, Claim 17, Claim 19, Claim 21, Claim 23, Claim 27, Claim 29, Claim 31, Claim 33.
- These suggest at least 10 distinct XRPD-defined crystalline-form claim anchors plus additional dependent variants.
Business meaning: the estate is not one polymorph claim. It is a portfolio of XRPD fingerprints, increasing the probability that a competitor’s candidate solid form matches at least one asserted crystalline signature.
What is the likely claim hierarchy and how does it drive litigation positions?
Most-likely “assertion set”
In enforcement, patentees commonly select:
- Independents with minimal gating (e.g., Claim 1, Claim 19, Claim 21) for easier infringement comparisons, while
- supporting with broader enumerations (e.g., Claim 11 and multi-peak/d-spacing claims) to blunt defenses about measurement variability.
Most-likely defenses
Accused infringers will typically argue:
- their XRPD data shows required peaks or d-spacings outside the tolerance windows,
- differences arise from instrument/model, radiation wavelength, calibration, sample preparation, crystallinity, preferred orientation, or measurement conditions,
- the accused product is a different polymorph or amorphous/mixture form rather than the crystalline form claimed.
How do the provided claim specifics translate into a “checklist” for XRPD matching?
Below is a distilled “needed XRPD events” list taken directly from the claim language provided.
Peak-based anchors
- Claim 1: ~13.0 and ~17.3 ±0.5° (2θ)
- Claim 3: (sodium salt) plus ~19.9, ~22.0 or ~28.2 ±0.5°
- Claim 4: (sodium salt) ~16.5 ±0.5°
- Claim 5: (sodium salt) ~17.5 ±0.5°
- Claim 6: (sodium salt) ~22.3 ±0.5°
- Claim 7: (sodium salt) ~19.2; ~19.5 ±0.5° (or combination)
- Claim 8: (sodium salt) ~19.9; ~22.0; ~25.2; ~28.2 ±0.5° (or combination)
- Claim 9: (sodium salt) ~23.2; ~30.2; ~30.9; ~36.1 ±0.5°
- Claim 10: (sodium salt) ~13.0; ~17.3; ~19.9; ~22.0; ~28.2 ±0.5°
- Claim 11: a multi-peak pattern including ~13.0, ~16.5, ~17.3, ~17.5, ~19.2, ~19.5, ~19.9, ~22.0, ~22.3, ~23.2, ~25.2, ~28.2, ~30.2, ~30.9, ~36.1 ±0.5°
- Claim 12-16: d-spacing-defined equivalents
- Claim 17: expanded 2θ list including ~8.7, ~11.3, ~12.5, ~16.3, ~17.5, ~17.8, ~18.6, ~21.0, ~22.3, ~26.2, ~26.6, ~26.9, ~27.6, ~28.7, ~29.8, ~30.4, ~31.2, ~32.9, ~33.4, ~34.4, ~37.1, ~37.3, ~37.6, ~38.5 ±0.5°
- Claim 19: ~8.5 and ~24.3 ±0.5°
- Claim 20: adds ~18.4; ~18.7; ~24.0; ~25.7; ~27.4; ~28.8 ±0.5° (or combination)
- Claim 21: ~17.8 and ~18.6 ±0.5°
- Claim 22: adds multiple peaks including ~8.7; ~11.3; ~12.5; ~16.3; ~21.1; ~27.0; ~26.6; ~28.7 (or combination)
- Claims 23-26: alternative peak-pair anchor (~17.8 and ~18.6 ±0.5°) plus different dependent multi-peak lists
d-spacing anchors
- Claim 12: ~5.1 and ~6.8 ±0.2 nm
- Claim 13: plus ~5.4 ±0.2 nm
- Claim 14: plus ~3.2, ~4.0, ~4.5 ±0.2 nm (or combination)
- Claim 15: includes list of ~2.5, ~2.9, ~3.0, ~3.2, ~3.5, ~3.8, ~4.0, ~4.5, ~4.6, ~5.4 ±0.2 nm
- Claim 16: combines multiple d-spacings including ~2.5, ~2.9, ~3.0, ~3.2, ~3.5, ~3.8, ~4.0, ~4.5, ~4.6, ~5.1, ~5.4, ~6.8 ±0.2 nm
- Claim 18: ~2.3 to ~10.1 ±0.2 nm (multi-d list)
- Claim 27-34: additional d-spacing-defined crystalline forms with pairs and multi-d sets, including:
- Claim 27: ~3.7 and ~10.4 ±0.2 nm; Claim 28 adds ~3.1, ~3.3, ~3.5, ~3.7, ~4.7, ~4.8 ±0.2
- Claim 29: ~4.8 and ~5.0 ±0.2; Claim 30 adds multiple including ~3.1, ~3.3, ~3.4, ~4.2, ~5.4, ~7.1, ~7.8, ~10.1 ±0.2
- Claim 31: ~5.6 and ~9.0 ±0.2; Claim 32 adds ~3.2, ~3.6, ~3.9, ~4.0, ~5.9, ~6.2 ±0.2
- Claim 33: ~4.9 and ~13.6 ±0.2; Claim 34 adds ~4.6, ~5.7, ~6.1 ±0.2
How does this crystalline-form patent landscape compare to typical generic launch risk?
Crystalline-form XRPD patents are often used to block “same API, different solid form” attempts. Generic risk depends on whether the reference product’s marketed solid state matches a claimed XRPD fingerprint.
Key scenarios
-
Generic uses reference product crystalline form
High risk: XRPD likely matches one or more asserted claims (especially multi-peak enumerations).
-
Generic uses a different polymorph
Risk depends on whether the alternative polymorph’s hallmark peaks/d-spacings overlap within tolerance with any asserted claims. With multiple anchors (claims 1, 19, 21, 17, 12 etc.), overlap risk increases.
-
Generic uses mixture or partially crystalline material
Risk depends on whether the required peaks/d-spacings are still detected with enough intensity to be considered the claimed crystalline form.
What is the patent “estate” relationship: is 8,471,025 likely core or incremental?
Based on claim structure alone, US 8,471,025 is incremental in the sense that it claims:
- a specific crystalline form rather than the underlying chemical scaffold broadly (the scaffold appears baked into the claim but not claimed as an unconstrained compound).
Enforcement implication: this type of patent is often paired with:
- earlier compound patents (if any),
- earlier or later crystalline form patents covering other polymorphs,
- formulation or process patents covering manufacture of that crystalline form.
That said, a complete estate map (other US patents, publication numbers, family members, and overlaps) cannot be generated from the claim text alone.
Orange Book status, FDA listings, Paragraph IV, and litigation: what is the status?
No Orange Book listing, FDA approval, patent registration numbers, expiration dates, exclusivity dates, or Paragraph IV/litigation facts are provided in the input. A litigation- and regulatory-timeline landscape cannot be produced without those external case and registry identifiers.
How strong is the claim protection in legal terms based on the claim mechanics?
Strength factors inherent in the claim text:
- Objective measurement parameters (XRPD peaks and d-spacings) reduce subjectivity.
- Multiple independently-defined crystalline forms and fingerprints expand coverage breadth.
- Presence of tolerance windows gives the patentee room to argue infringement even under routine measurement variability.
Weakness factors inherent in the claim text:
- The use of numerous enumerated peak/d-spacing values increases the chance that an accused product can show at least one required parameter outside tolerance, depending on the comparator and measurement approach.
- If claim construction narrows “characteristic peak” definition, the minimal two-peak anchors may become vulnerable to disputes about whether other peaks confirm the same crystalline form.
Overall, the patent’s enforcement posture is likely anchored on matching the XRPD fingerprints with corroborating patterns.
Key claim-by-claim scope map (condensed)
| Claim |
Covered subject |
Measurement definition |
| 1 |
Crystalline form of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide or salt |
XRPD peaks at ~13.0 and ~17.3 ±0.5° 2θ |
| 2 |
Sodium salt only |
Depends on Claim 1; sodium-specific |
| 3-10 |
Sodium salt variants |
Add specific additional peaks (2θ) per claims |
| 11 |
Crystalline form with full peak set |
Multi-peak XRPD list including ~13.0 and ~36.1 ±0.5° |
| 12-16 |
Crystalline form variants |
d-spacing sets including ~5.1 and ~6.8 ±0.2 nm |
| 17 |
Crystalline form variant |
Expanded 2θ list incl. many peaks through ~38.5 ±0.5° |
| 18 |
Crystalline form variant |
d-spacing list incl. ~2.3 to ~10.1 ±0.2 nm |
| 19-20 |
Crystalline form variant |
Peaks at ~8.5 and ~24.3 ±0.5° plus additional peaks |
| 21-26 |
Crystalline form variant(s) |
Peaks at ~17.8 and ~18.6 ±0.5° plus additional peaks |
| 27-28 |
Crystalline form variant |
d-spacings ~3.7 and ~10.4 ±0.2 nm plus others |
| 29-30 |
Crystalline form variant |
d-spacings ~4.8 and ~5.0 ±0.2 nm plus others |
| 31-32 |
Crystalline form variant |
d-spacings ~5.6 and ~9.0 ±0.2 nm plus others |
| 33-34 |
Crystalline form variant |
d-spacings ~4.9 and ~13.6 ±0.2 nm plus others |
Key Takeaways
- US 8,471,025 is an XRPD-defined crystalline form patent covering trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and its pharmaceutically acceptable salts, with a sodium salt pathway in dependent claims.
- The claim set uses multiple crystalline-form anchors, including two-hallmark 2θ gating claims (easier to match) and multi-peak/multi-d-spacing fingerprints (higher proof burden for accused parties).
- Infringement/avoidance turns on XRPD alignment within ±0.5° (2θ) and ±0.2 nm (d-spacing) tolerances.
- A complete US estate map (other family members, prosecution history, Orange Book registration, expiration dates, Paragraph IV challenges, and litigation outcomes) cannot be derived from the provided claim text alone.
FAQs
1) What element of US 8,471,025 most directly determines infringement?
XRPD characteristic peak positions (2θ) and/or d-spacing values matching the claimed crystalline signatures within the stated tolerances.
2) Can a competitor avoid the patent by changing the salt form?
Possibly, but Claim 1 covers the compound “or pharmaceutically acceptable salt,” while dependent claims add sodium salt-specific XRPD patterns. Avoidance requires both salt selection and XRPD non-match.
3) Which claims are easiest to assert based on the fewest required XRPD parameters?
The two-peak gating claims such as Claim 1 (~13.0 and ~17.3 ±0.5°), Claim 19 (~8.5 and ~24.3 ±0.5°), and Claim 21 (~17.8 and ~18.6 ±0.5°).
4) Does the patent appear to claim a manufacturing method or only the solid form?
Based on the provided claims, it is directed to crystalline forms defined by XRPD, not a manufacturing process or dosage form.
5) Are both peak-based and d-spacing-based definitions asserted?
Yes. The claims include both 2θ peak listings and d-spacing lists, creating multiple independent routes to infringement.
References
- United States Patent No. 8,471,025. (Claims provided in prompt text).
More… ↓
⤷ Start Trial
|
